{"id":"NCT00553475","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy","officialTitle":"Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2007-11-05","resultsPosted":"2010-06-22","lastUpdate":"2021-01-25"},"enrollment":314,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathy, Painful"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]},{"type":"DRUG","name":"pregabalin","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pregabalin 300 mg/day","type":"EXPERIMENTAL"},{"label":"Pregabalin 600 mg/day","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy and safety of pregabalin at 300 mg/day and 600 mg/day (BID) in patients with painful diabetic peripheral neuropathy.","primaryOutcome":{"measure":"Change From Baseline to Study Endpoint in Mean Weekly Pain Scores","timeFrame":"From baseline to Week 13 or up to study discontinuation (Study Endpoint)","effectByArm":[{"arm":"Placebo","deltaMin":-1.2,"sd":0.21},{"arm":"Pregabalin 300 mg/Day","deltaMin":-1.82,"sd":0.22},{"arm":"Pregabalin 600 mg/Day","deltaMin":-1.94,"sd":0.32}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0075"},{"comp":"OG000 vs OG002","p":"0.0254"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":49,"countries":["Japan"]},"refs":{"pmids":["31802967","30521533","30206821","30084288","27611736"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081163&StudyName=Randomized%2C%20Double-Blind%2C%20Multicenter%2C%20Placebo-Controlled%20Study%20Of%20Pregabalin%20For%20Pain%20Associated%20With%20Diabetic%20Peripheral%20Neuropathy"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":135},"commonTop":["Somnolence","Dizziness","Nasopharyngitis","Oedema peripheral","Weight increased"]}}